Comprehensive support for equity and derivative trading. 4. Zerodha Kite Zerodha Kite is known for its user-friendly interface and low brokerage charges. Whether you’re a beginner or an ...

Nithin Kamath, CEO of Zerodha, has raised concerns about fake apps mimicking financial institutions, urging RBI for stricter countermeasures. He praised RBI's new '.bank.in' domain but called for ...

Zerodha CEO Nithin Kamath elucidates SEBI’s new rules on retail algo trading. Retail traders must now register with stock exchanges and partner with brokers if selling strategies. In the X post ...

Nithin Kamath, co-founder and Chief Executive Officer at Zerodha, on Tuesday shared that the company now has more than 1.6 crore users without ever advertising and 30 per cent of these investors ...

Over 1.6 crore Indians now invest and trade on Zerodha, trusting the platform with ₹6 lakh crores of their assets. What sets Zerodha apart isn’t just its scale but how it got there—without ...

(X) Investing platform Zerodha now boasts over 1.6 crore users managing assets worth Rs 6 lakh crores, co-founder Nithin Kamath shared in a LinkedIn post. Interestingly, Zerodha’s remarkable ...

Online brokerage platform Zerodha's Chief Executive Officer Nithin Kamath cautioned people against the metaphorical “US Empire”, pointing at how United States President Donald Trump has gone ...

Kites of different hues and shapes adorned the sky at Tannirbhavi beach as the two-day ONGC-MRPL Mangaluru International Kite Festival began on Saturday. Organised by Team Mangalore, this is the ...

Q: Is Kites Flop or Hit? A: The performance of Kites was Flop. Q: What is the overall Box Office Collection of Kites? A: No Data Found.. Q: What is the Day 1 Box Office Collection of Kites?

Zerodha Kite is another popular stock trading app in India. It is widely known for its low brokerage fees and intuitive design. The app offers a clutter-free interface that is perfect for beginners.

The Supreme Court on Monday stayed trial court proceedings against Congress leader Rahul Gandhi in a criminal defamation case filed against him for alleged defamatory remarks against Union Home ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.